CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
docetaxel +2 moredrug
Likely dose
fluorouracil 85 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00711243
NCT00711243Phase 2Completed
CompareCT.gov

A Phase I/II Study of Taxotere, Oxaliplatin, and 5- Fluorouracil

Northwestern University·interventional·Posted Jul 8, 2008·Updated Feb 26, 2019

In Brief

A Phase 2 clinical trial evaluating docetaxel, fluorouracil, and 1 other intervention for Gastric Cancer and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 59 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel when given with oxaliplatin and fluorouracil and to see how well they work in treating patients with metastatic or unresectable stomach cancer, gastroesophageal junction cancer, or other solid tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 8, 2008
Enrollment StartApr 20, 2005
Primary CompletionDec 15, 2008
Study CompletionFeb 25, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.0 years ago

Interventions

docetaxeldrug

Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.

fluorouracildrug

Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.

oxaliplatindrug

Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel